Skip to content

Mechanical Bowel Preparation and Oral Antibiotics Before Rectal Cancer Surgery

Mechanical Bowel Preparation and Oral Antibiotics Before Rectal Cancer Surgery: a Multi Center Double-Blinded Randomized Controlled Trial (PREPACOL2 Study)

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03491540
Acronym
PREPACOL2
Enrollment
414
Registered
2018-04-09
Start date
2018-09-03
Completion date
2023-12-12
Last updated
2024-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Cancer Surgery

Keywords

Mechanical Bowel Preparation (MBP), Oral antibiotics, Rectal cancer surgery, Surgical site infection

Brief summary

This study aims to demonstrate that a preoperative combination of mechanical bowel preparation and oral antibiotics, before elective laparoscopic rectal cancer surgery, is associated with a reduction of postoperative surgical site infection rate, as compared to mechanical bowel preparation alone Our hypothesis is that a preoperative colonic preparation including a combination of mechanical bowel preparation and oral antibiotics before elective laparoscopic rectal cancer surgery is associated with a reduced rate of 30-day postoperative surgical site infection, as compared to mechanical bowel preparation alone

Detailed description

This study aims to demonstrate that a preoperative combination of mechanical bowel preparation and oral antibiotics, before elective laparoscopic rectal cancer surgery, is associated with a reduction of postoperative surgical site infection rate, as compared to mechanical bowel preparation alone. This study's hypothesis is that a preoperative colonic preparation including a combination of mechanical bowel preparation and oral antibiotics before elective laparoscopic rectal cancer surgery is associated with a reduced rate of 30-day postoperative surgical site infection, as compared to mechanical bowel preparation alone Preoperative mechanical bowel preparation (MBP) has been proposed in an attempt to reduce the colonic fecal load and to limit the risk of surgical site contamination, thus theoretically limiting the risk of postoperative surgical site infection (SSI). However, the benefit of such MBP before colorectal surgery is related to type of procedure performed. Indeed, several randomized controlled trials (RCT) and meta-analyses have demonstrated the absence of benefit of MBP before colon cancer surgery, whereas a recent RCT suggested that MBP before rectal cancer surgery was associated to a significant reduction of postoperative SSI, as compare to the absence of preoperative MBP. Recent studies suggested that the adjunction of oral antibiotics during MBP could help efficiently reduce the risk of postoperative SSI. Indeed, a recent meta-analysis of RCT have suggested that patients preoperatively receiving both MBP and oral antibiotics were exposed to a significantly reduced risk of postoperative SSI, as compared to patients receiving only preoperative MBP. This result was confirmed in a recent RCT which compared preoperative MBP and oral antibiotics versus MBP alone in a heterogeneous population of patients who underwent laparoscopic colonic or rectal surgery. However, to date, no RCT compared the outcomes of an MBP with oral antibiotics to MBP without oral antibiotics in a homogeneous cohort of patients undergoing rectal cancer surgery. This study aims to demonstrate that a preoperative combination of mechanical bowel preparation and oral antibiotics, before elective laparoscopic rectal cancer surgery, is associated with a reduction of postoperative surgical site infection rate, as compared to mechanical bowel preparation alone.

Interventions

Mechanical bowel preparation : Sennosides colonic preparation (X-PREP) 1 per day, on day -2 and day -1

Oral gentamycin: Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials

Oral ornidazole : Ornidazole 1 g per day (2 tablet per day), on day -2 and day -1; In tablets

Placebo for oral gentamycin : Same presentation as oral gentamycin x4 per day on day -2 and day -1

Placebo for oral ornidazole : Same presentation as oral ornidazole 1g per day (2 tablets per day) on day -2 and day -1

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Masking description

Both participants and investigators are unaware of the intervention assignment

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged 18 or more * Scheduled to undergo elective restorative laparoscopic cancer of the rectal (\<15 cm from the anal margin) with sphincter preservation * With Signed consent * And affiliated to the French social security system

Exclusion criteria

* Emergent surgery * Scheduled total colo-proctectomy * Scheduled abdominoperineal restion with definitive colostomy * Scheduled associated concomitant resection of another organ (liver, etc.) * Active bacterial infection at the time of surgery or recent antibiotic therapy (up to 15 days before surgery) * Associated inflammatory bowel disease * Patients with known colonization with multidrug-resistant enterobacteriacea * History of allergy or contraindication to the Ornidazole, Gentamycin, X-PREP or to any of the excipients of the drugs used. * Cirrhosis of grade B and C (Child-Pugh classification) * Myasthenia * Allergy to one of the other treatments administered for the purpose of the trial (including betadine) * Patient suffering from severe central neurologic diseases, fixed or progressive. * Pregnant patients * Refusal to participate or inability to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Postoperative 30-day surgical site infection (SSI).30 daysSSI will be defined and classified as superficial, deep and/or organ-space infection on the basis of validated and well-defined criteria developed by the Centers for Disease Control and Prevention (CDC), validated in French by the Comité technique des infections nosocomiales et des infections liées aux soins.

Secondary

MeasureTime frameDescription
Severe postoperative morbidity30 daysIncluding all complications graded 3 or more according to the Clavien-Dindo classification, and occurring within 30 days after surgery.
Postoperative mortality30 daysIncluding all deaths occurring within 30 days after surgery.
Postoperative anastomotic leakage90 daysDefined as the passing of any intra-colonic content (air, liquid, intestinal content, or radiological contrast) through an anastomosis or by an peri-anastomotic abscess, even in the absence of intra-colonic content leak through the anastomosis, observed in drainages, surgical incision, vagina, during a surgical procedure or on a radiological examination, occurring within 90 days after surgery.
Postoperative length of hospital stayUp to 90 daysCalculated from the day of surgery to the day of hospital discharge.
Unplanned hospitalization90 daysDefined as any unplanned hospitalization between surgery and postoperative day 90.
Overall postoperative morbidity30 daysIncluding all postoperative complications occurring within 30 days after surgery, defined and classified according to the Clavien-Dindo classification.
Clostridium difficile colitis occurrence30 daysDefined as clinical symptoms of clostridium difficile colitis with at least 1 stool sample positive for Clostridium difficile toxin A/B as detected by enzyme-linked immunosorbent assay within 30 days after surgery.
Rate of multi-resistant bacteria carriageThe day before or the day of surgeryDefined as rate of multi-resistant bacteria carriage
Date of adjuvant chemotherapy beginning90 daysIf indicated
Temporary stoma closure rate90 daysDefine as temporary stoma closure
Tolerance of the colonic preparationThe day before surgeryEvaluated using a dedicated questionnaire performed the evening before surgery.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026